Treace Medical Concepts reported solid growth in the first quarter of 2025 with a 3% increase in revenue to $52.6 million and significant improvements in adjusted EBITDA and net loss compared to the same period in the previous year. The company also expanded its bunion technology portfolio with new product launches and continued to build clinical evidence.
Generated revenue of $52.6 million in the first quarter 2025, representing growth of 3% over the same period in 2024.
Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024.
Improved adjusted EBITDA by 53% to $(3.8) million in the first quarter 2025 compared to $(8.3) million in the same period in 2024.
Expanded bunion technology portfolio through limited market releases of new systems and expects additional launches in 2025.
The company is reaffirming full-year 2025 revenue guidance and continues to expect breakeven Adjusted EBITDA for the full year.
Analyze how earnings announcements historically affect stock price performance